BioTech Medics, Inc. Announces Reverse Stock Split and Symbol Change
17 November 2007 - 1:25AM
Marketwired
DALLAS, TX , now (PINKSHEETS: BMCS)] announces the notice from
NASDAQ according to The Exchange Act Rule 10b-17 to approve a
reverse stock split and symbol change from BTME to BMCS effective
at the open of the stock market today.
On October 25, 2007, pursuant to Section 78.320 of the Nevada
Revised Statutes, a majority of shareholders of BioTech Medics,
Inc. consented to amend the Articles of Incorporation to a 1 for 20
reverse stock split for the outstanding shares of common stock. As
a result of the stock split, each twenty (20) shares of common
stock issued and outstanding before the effectiveness of the split
shall be exchanged for one (1) share of common stock after the
split. No small shareholders will be cashed out. Fractional shares
will be rounded up to the next whole share. The Amendment was filed
with the Nevada Secretary of State on Nov. 5, 2007. The outstanding
shares (o/s) will be approximately 8.09 million at the open of
today's market. The authorized shares remain at 500 million, there
are no preferred shares issues.
Shareholders will not be required to return their old stock
certificates for new certificates; however, shareholders may
voluntarily exchange their BTME shares for BMCS shares for a fee
charged by Transfer Online. Their web site is
www.transferonline.com.
The Board of Directors together with a majority of shareholders
voted on the reverse stock split to better achieve the business
purposes of the Company and to increase the price of the stock to
attract investors.
BioTech Medics is a ten-year-old company and owns, operates and
affiliates with Pain Management & Wellness Centers that have
non-hazardous high-powered therapeutic medical Class IIIB lasers
that are used for the reduction of acute and chronic muscular,
skeletal and/or arthritic pain. Conditions such as back pain,
arthritis, carpal tunnel, joint and nerve pain, sports injuries,
accidents and work-related injuries can be treated easily and
non-surgically in clinical sessions lasting less than 30 minutes in
one of BioTech's Pain Management & Well Centers.
BioTech is the patent holder of SHBAN(TM) Hand Sanitizer which
is an anti-microbial clinically proven to kill Staph and the Avian
Bird Flu Virus together with most common germs, fungus and
bacteria. SHBAN is superior to other hand sanitizers because SHBAN
has no alcohol, is non-toxic (when used as directed) and leaves an
invisible protective film on your hands for long-lasting
protection.
Safe Harbor for Forward-Looking Statements
This release contains forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995
(the "Act"). Such statements are subject to certain risks and
uncertainties and actual results could differ materially from those
expressed in any of the forward-looking statements. The FDA has
made no evaluation of SHBAN. SHBAN is not made to diagnose, cure or
treat any disease.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: Investor Relations 1-972-274-5533
BioTech Medics (PK) (USOTC:BMCS)
Historical Stock Chart
From Mar 2025 to Apr 2025
BioTech Medics (PK) (USOTC:BMCS)
Historical Stock Chart
From Apr 2024 to Apr 2025